Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director | May 14, 2026 | May 14, 2026 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date May 14, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-05-13 | Direct | 9,149 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 9,149 · Balance 9,149 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
TANDEM DIABETES CARE INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,434 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Exercise / conversion · Acquired 8,759 · Balance 24,434 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 10,220 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 10,220 · Balance 10,220 F3: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 8,759 · Balance 0 F3: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F5: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,112 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,112 F1: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 7,568 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,568 F2: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over these securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002.
F2: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over these securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein.
F3: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F4: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan.
F5: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SENOMYX INC
Report date November 02, 2018 · Filed November 02, 2018
Section 16 reporting ended · disclosed 2018-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2028-05-23 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 8,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000073 · wk-form4_1779480372.xml · derivative · entry 5 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F5 · derivative.exercise_date: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan. F5 · derivative.expiration_date: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 8,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000073 · wk-form4_1779480372.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 10,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000073 · wk-form4_1779480372.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,220 Underlying: Common Stock · 10,220 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document |
| May 14, 2026 Filed May 14, 2026 22:15 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 9,149 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001238935-26-000003 · ownership.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,149 Underlying: Common Stock · 9,149 shares Expires 2036-05-13 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:51 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 2,775 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001411690-25-000070 · wk-form4_1749761462.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,775 Underlying: Common Stock · 2,775 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:03 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 4,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000104 · wk-form4_1748030581.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 22, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F5 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:03 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 4,387 | $20.64 | $90,547.68 |
DisclosureSEC source: 0001438133-25-000104 · wk-form4_1748030581.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:03 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 8,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000104 · wk-form4_1748030581.xml · derivative · entry 5 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,759 Underlying: Common Stock · 8,759 shares Expires not disclosed F6 · security: Awarded on May 21, 2025 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F5 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:22 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001411690-24-000031 · wk-form4_1718914933.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 24, 2024 Filed May 24, 2024 23:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 4,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000125 · wk-form4_1716592955.xml · derivative · entry 5 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 24, 2023 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F5 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document |
| May 24, 2024 Filed May 24, 2024 23:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 4,434 | $51.73 | $229,370.82 |
DisclosureSEC source: 0001438133-24-000125 · wk-form4_1716592955.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2024 Filed May 24, 2024 23:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 4,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000125 · wk-form4_1716592955.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,387 Underlying: Common Stock · 4,387 shares Expires not disclosed F3 · security: Awarded on May 22, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F5 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:14 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001411690-23-000052 · wf-form4_168694647426200.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:13 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-23-000108 · wf-form4_168513194653961.xml · derivative · entry 5 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F8 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. F8 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:13 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-23-000108 · wf-form4_168513194653961.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:13 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRSU 2023 05 24 · Derivative | 4,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-23-000108 · wf-form4_168513194653961.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,434 Underlying: Common Stock · 4,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 24, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. F5 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:26 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 164,422 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-036311 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,422 Underlying: Common Stock · 164,422 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 25, 2022 Filed May 28, 2022 01:49 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 2,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-22-000129 · wf-form4_165370256085286.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,757 Underlying: Common Stock · 2,757 shares Expires not disclosed F3 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. F5 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document |
| May 18, 2022 Filed May 19, 2022 23:53 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-22-000091 · wf-form4_165300438423893.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. F5 · derivative.expiration_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document |
| May 18, 2022 Filed May 19, 2022 23:53 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-22-000091 · wf-form4_165300438423893.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2022 Filed May 10, 2022 21:01 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionWarrant · Derivative | 238 | $73.73 Strike: $73.73 | $17,546.79 |
DisclosureSEC source: 0001438133-22-000065 · wf-form4_165221619881112.xml · derivative · entry 7 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The expiration date for this warrant is August 31, 2022. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| May 05, 2022 Filed May 10, 2022 21:01 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionWarrant · Derivative | 135 | $73.73 Strike: $73.73 | $9,953.01 |
DisclosureSEC source: 0001438133-22-000065 · wf-form4_165221619881112.xml · derivative · entry 6 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The expiration date for this warrant is August 31, 2022. F3 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 05, 2022 Filed May 10, 2022 21:01 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 90 | $111.73 | $10,055.70 |
DisclosureSEC source: 0001438133-22-000065 · wf-form4_165221619881112.xml · nonDerivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,568 F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F3 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 05, 2022 Filed May 10, 2022 21:01 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 158 | $111.73 | $17,653.34 |
DisclosureSEC source: 0001438133-22-000065 · wf-form4_165221619881112.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,112 F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| May 05, 2022 Filed May 10, 2022 21:01 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 135 | $73.73 | $9,953.01 |
DisclosureSEC source: 0001438133-22-000065 · wf-form4_165221619881112.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F3 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 05, 2022 Filed May 10, 2022 21:01 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 238 | $73.73 | $17,546.79 |
DisclosureSEC source: 0001438133-22-000065 · wf-form4_165221619881112.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,500 | $129.09 | $322,712.50 |
DisclosureSEC source: 0001438133-21-000161 · wf-form4_163121946475437.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,032 F3 · kind: The shares were given as a bona fide gift to the Chris and Rebecca Twomey Family Foundation at the San Diego Foundation. F4 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 304 | $123.00 | $37,392.00 |
DisclosureSEC source: 0001438133-21-000161 · wf-form4_163121946475437.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,532 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 22:38 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 4,696 | $115.01 | $540,077.10 |
DisclosureSEC source: 0001438133-21-000159 · wf-form4_163070867372263.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,836 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $115.00 to $115.21. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F5 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 22:38 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 4,000 | $115.00 | $460,000.40 |
DisclosureSEC source: 0001438133-21-000159 · wf-form4_163070867372263.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,523 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $115.00 to $115.12. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:47 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 40,751 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001209191-21-052601 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,751 Underlying: Common Stock · 40,751 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following June 10, 2021, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 21:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 3,000 | $105.00 | $315,000.00 |
DisclosureSEC source: 0001438133-21-000110 · wf-form4_162768227313960.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,523 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F5 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 21:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,500 | $104.89 | $262,212.50 |
DisclosureSEC source: 0001438133-21-000110 · wf-form4_162768227313960.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,532 F3 · kind: The shares were given as a bona fide gift to the Chris and Rebecca Twomey Family Foundation at the San Diego Foundation. F4 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 21:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 5,000 | $105.00 | $525,000.00 |
DisclosureSEC source: 0001438133-21-000110 · wf-form4_162768227313960.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 15,032 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:17 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 7,528 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-21-040406 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 Underlying: Common Stock · 7,528 shares Expires 2031-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 23:19 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 1,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-21-000082 · wf-form4_162258956819285.xml · derivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the Company. F5 · kind: This RSU award was granted on May 27, 2020. 100% of the RSU vested on May 27, 2021. F6 · derivative.exercise_date: RSU vest as to one-hundred percent (100%) of the total number of shares subject to the RSU on 5/27/2021. F6 · derivative.expiration_date: RSU vest as to one-hundred percent (100%) of the total number of shares subject to the RSU on 5/27/2021. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 23:19 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 1,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-21-000082 · wf-form4_162258956819285.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionWarrant · Derivative | 135 | $73.73 Strike: $73.73 | $9,953.01 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · derivative · entry 7 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.expiration_date: The expiration date for this warrant is August 31, 2021. F3 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionWarrant · Derivative | 189 | $73.73 Strike: $73.73 | $13,934.21 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · derivative · entry 6 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.expiration_date: The expiration date for this warrant is August 31, 2021. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 112 | $89.03 | $9,971.36 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · nonDerivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 14,523 F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F3 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 157 | $89.03 | $13,977.71 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,032 F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 135 | $73.73 | $9,953.01 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 14,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F3 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 189 | $73.73 | $13,934.21 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. F2 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| May 18, 2021 Filed May 21, 2021 01:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 2,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-21-000050 · wf-form4_162156078319824.xml · derivative · entry 5 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,205 Underlying: Common Stock · 2,205 shares Expires not disclosed F4 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F6 · derivative.exercise_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. F6 · derivative.expiration_date: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 22:30 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,401 | $95.00 | $133,095.00 |
DisclosureSEC source: 0001438133-21-000028 · wf-form4_161921700162090.xml · nonDerivative · entry 5 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 14,500 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F4 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 22:30 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,500 | $93.64 | $234,087.50 |
DisclosureSEC source: 0001438133-21-000028 · wf-form4_161921700162090.xml · nonDerivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,000 F5 · kind: The shares were given as a bona fide gift to the Chris and Rebecca Twomey Family Foundation at the San Diego Foundation. F6 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 22:30 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 3,401 | $95.00 | $323,095.00 |
DisclosureSEC source: 0001438133-21-000028 · wf-form4_161921700162090.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,500 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F3 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 22:30 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,599 | $95.02 | $151,933.94 |
DisclosureSEC source: 0001438133-21-000028 · wf-form4_161921700162090.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 15,901 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $95.00 to $95.24. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F4 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 22:30 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,599 | $95.02 | $151,933.78 |
DisclosureSEC source: 0001438133-21-000028 · wf-form4_161921700162090.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,901 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2021. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $95.00 to $95.24. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| July 31, 2020 Filed Aug 5, 2020 00:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 2,500 | $110.00 | $275,000.00 |
DisclosureSEC source: 0001438133-20-000123 · wf-form4_159658620814357.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 17,500 F6 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.